Rigel director reports initial share holdings

Q: What insider position does Michael Patrick Miller hold at Rigel Pharmaceuticals (RIGL)?

Michael Patrick Miller is reported as a director of Rigel Pharmaceuticals. The filing indicates he is not an officer and not a 10% owner, so this disclosure focuses on his board-level role and associated equity holdings in the company.

Q: How many Rigel Pharmaceuticals (RIGL) common shares does Michael Patrick Miller own?

Michael Patrick Miller directly owns 187 shares of Rigel Pharmaceuticals common stock. These shares are held in direct form, meaning they are attributed personally to him rather than through an intermediate entity such as a trust, partnership, or other indirect ownership vehicle.

Q: What stock options does Michael Patrick Miller hold in Rigel Pharmaceuticals (RIGL)?

He holds a stock option for 625 shares of common stock with an exercise price of $16.05 per share, expiring on October 3, 2034. This option, if exercised, would allow him to purchase Rigel shares at that fixed price.

Q: How is Michael Patrick Miller’s Rigel (RIGL) stock option vesting structured?

Of the 625-share option, 375 shares are already vested. The remaining 250 shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, creating a staged vesting over those four months.

Q: Is Michael Patrick Miller’s ownership in Rigel (RIGL) direct or through another entity?

Both the 187 common shares and the 625-share stock option are reported as direct (D) ownership. The disclosure does not describe any trust, partnership, or other indirect ownership structure associated with these positions.

Q: Does the Rigel (RIGL) Form 3 for Michael Patrick Miller show any recent trades?

The disclosure lists holdings rather than specific buy or sell transactions. It reports his beneficial ownership of 187 common shares and a 625-share stock option, serving as an initial snapshot of his equity position as a company director.

Rigel Pharmaceuticals director Michael Patrick Miller reported his initial ownership of company securities.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals director Michael Patrick Miller reported his initial ownership of company securities. He directly holds 187 shares of common stock and a stock option for 625 shares at an exercise price of $16.05 per share, expiring on October 3, 2034.

Of this option, 375 shares are already vested. The remaining 250 option shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, giving a clear schedule for when he gains full option rights.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MILLER MICHAEL PATRICK

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 625 contracts (Direct); Common Stock — 187 shares (Direct)

Footnotes (1)

F1. 375 shares subject to this option are vested, and the remaining 250 shares subject to this option will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position does Michael Patrick Miller hold at Rigel Pharmaceuticals (RIGL)?

Michael Patrick Miller is reported as a director of Rigel Pharmaceuticals. The filing indicates he is not an officer and not a 10% owner, so this disclosure focuses on his board-level role and associated equity holdings in the company.

How many Rigel Pharmaceuticals (RIGL) common shares does Michael Patrick Miller own?

Michael Patrick Miller directly owns 187 shares of Rigel Pharmaceuticals common stock. These shares are held in direct form, meaning they are attributed personally to him rather than through an intermediate entity such as a trust, partnership, or other indirect ownership vehicle.

What stock options does Michael Patrick Miller hold in Rigel Pharmaceuticals (RIGL)?

He holds a stock option for 625 shares of common stock with an exercise price of $16.05 per share, expiring on October 3, 2034. This option, if exercised, would allow him to purchase Rigel shares at that fixed price.

How is Michael Patrick Miller’s Rigel (RIGL) stock option vesting structured?

Of the 625-share option, 375 shares are already vested. The remaining 250 shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, creating a staged vesting over those four months.

Is Michael Patrick Miller’s ownership in Rigel (RIGL) direct or through another entity?

Both the 187 common shares and the 625-share stock option are reported as direct (D) ownership. The disclosure does not describe any trust, partnership, or other indirect ownership structure associated with these positions.

Does the Rigel (RIGL) Form 3 for Michael Patrick Miller show any recent trades?

The disclosure lists holdings rather than specific buy or sell transactions. It reports his beneficial ownership of 187 common shares and a 625-share stock option, serving as an initial snapshot of his equity position as a company director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/03/2026 - 04:04 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MILLER MICHAEL PATRICK

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/01/2026

3. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	187	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	10/03/2034	Common Stock	625	$16.05	D

Explanation of Responses:

1. 375 shares subject to this option are vested, and the remaining 250 shares subject to this option will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Raymond Furey (Attorney-in-Fact)	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR